Showing results (151-160 of 261) with videos related to
Sort By:
Pageof 27
Journal of Clinical Pharmacology|November 7, 2017
Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque PsoriasisRichard G Langley, Sree Kasichayanula, Mona Trivedi, et al.The British Journal of Dermatology|May 7, 2009
Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trialD Y M Leung, J M Hanifin, D M Pariser, et al.Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.The British Journal of Dermatology|April 27, 2012
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisA B Gottlieb, R G Langley, B E Strober, et al.The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.Dermatology and Therapy|October 27, 2021
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.Journal of the American Academy of Dermatology|January 19, 2016
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, David M Pariser, et al.Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.Animal Cognition|August 11, 2017
A novel continuous inhibitory-control task: variation in individual performance by young pheasants (Phasianus colchicus)Christina Meier, Sara Raj Pant, Jayden O van Horik, et al.Journal of the American Academy of Dermatology|September 13, 2017
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment RegistryDavid Fiorentino, Vincent Ho, Mark G Lebwohl, et al.Pageof 27